[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Immuron Ltd ADR (IMRN)

Immuron Ltd ADR (IMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,282
  • Shares Outstanding, K 8,071
  • Annual Sales, $ 4,720 K
  • Annual Income, $ -3,380 K
  • EBIT $ 0 M
  • EBITDA $ -4 M
  • 60-Month Beta 1.15
  • Price/Sales 1.54
  • Price/Cash Flow N/A
  • Price/Book 1.11

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +12.75%
on 08/07/26
1.2200 -5.74%
on 08/19/26
+0.0550 (+5.02%)
since 07/28/26
3-Month
0.9864 +16.59%
on 07/07/26
1.6000 -28.13%
on 06/01/26
-0.0600 (-4.96%)
since 05/28/26
52-Week
0.6765 +69.99%
on 12/30/25
2.3900 -51.88%
on 10/16/25
-0.6700 (-36.81%)
since 08/28/25

Most Recent Stories

More News
Immuron Reports FY26 Preliminary Results

MELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for...

IMRN : 1.1500 (-1.29%)
IMC.AX : 0.039 (+5.41%)
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

MELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven...

IMRN : 1.1500 (-1.29%)
IMC.AX : 0.039 (+5.41%)
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

Sales Highlights (unaudited):Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp)2H FY26 sales AUD$3.5 million up 7% on...

IMRN : 1.1500 (-1.29%)
IMC.AX : 0.039 (+5.41%)
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyImmuron is seeking a partner to support clinical development through...

IMRN : 1.1500 (-1.29%)
IMC.AX : 0.039 (+5.41%)
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-month...

IMRN : 1.1500 (-1.29%)
Immuron Double Digit 3Q Sales Growth

Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million up 7% on prior...

IMRN : 1.1500 (-1.29%)
IMC.AX : 0.039 (+5.41%)
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month...

IMRN : 1.1500 (-1.29%)
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...

IMRN : 1.1500 (-1.29%)
IMC.AX : 0.039 (+5.41%)
Immuron Reports HY26 Results and Strategic Reset

Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a

IMRN : 1.1500 (-1.29%)
IMC.AX : 0.039 (+5.41%)
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month...

IMRN : 1.1500 (-1.29%)

Business Summary

Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale,...

See More

Key Turning Points

3rd Resistance Point 1.2000
2nd Resistance Point 1.1900
1st Resistance Point 1.1700
Last Price 1.1500
1st Support Level 1.1400
2nd Support Level 1.1300
3rd Support Level 1.1100

See More

52-Week High 2.3900
Fibonacci 61.8% 1.7354
Fibonacci 50% 1.5333
Fibonacci 38.2% 1.3311
Last Price 1.1500
52-Week Low 0.6765

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.